IUGNF Stock - Imugene Limited
Unlock GoAI Insights for IUGNF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $4.40M | $4.97M | $11.78M | $12.97M | $7.23M |
| Gross Profit | $4.40M | $4.97M | $9.57M | $10.56M | $5.27M |
| Gross Margin | 100.0% | 100.0% | 81.3% | 81.4% | 72.9% |
| Operating Income | $-70,940,449 | $-153,717,801 | $-39,767,239 | $-37,941,000 | $-18,465,872 |
| Net Income | $-69,021,612 | $-149,681,000 | $-37,915,000 | $-37,869,000 | $-18,455,000 |
| Net Margin | -1569.8% | -3011.7% | -321.9% | -292.0% | -255.2% |
| EPS | $-0.32 | $-0.72 | $-0.21 | $-0.23 | $-0.13 |
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.
Visit WebsiteEarnings History & Surprises
IUGNFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 26, 2026 | — | — | — | — |
Q1 2025 | Feb 26, 2025 | $-0.01 | $-0.00 | +34.7% | ✓ BEAT |
Q4 2024 | Oct 30, 2024 | — | — | — | — |
Q3 2024 | Aug 30, 2024 | $-0.01 | $-0.01 | -11.2% | ✗ MISS |
Q2 2024 | Apr 18, 2024 | — | — | — | — |
Q1 2024 | Feb 28, 2024 | — | $-0.01 | — | — |
Q1 2024 | Jan 9, 2024 | — | $-0.00 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.00 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.00 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.00 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.00 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.00 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.00 | — | — |
Q4 2021 | Dec 30, 2021 | — | $-0.00 | — | — |
Q3 2021 | Sep 30, 2021 | $-0.00 | $-0.00 | -35.6% | ✗ MISS |
Q2 2021 | Jun 30, 2021 | — | $-0.00 | — | — |
Q1 2021 | Mar 31, 2021 | $-0.00 | $-0.00 | +13.3% | ✓ BEAT |
Q4 2020 | Dec 30, 2020 | — | $-0.00 | — | — |
Q3 2020 | Sep 30, 2020 | $-0.00 | $-0.00 | +52.0% | ✓ BEAT |
Q2 2020 | Jun 30, 2020 | — | $-0.00 | — | — |
Latest News
Frequently Asked Questions about IUGNF
What is IUGNF's current stock price?
What is the analyst price target for IUGNF?
What sector is Imugene Limited in?
What is IUGNF's market cap?
Does IUGNF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to IUGNF for comparison